Clinical Effect Analysis of Tenofovir Fumarate Dipivoxime in Treatment of Hepatitis B Cirrhosis
Objective To evaluate clinical value of tenofovir dipivoxil fumarate in treatment of patients with hepatitis B and cirrhosis.Methods The paper chose 82 patients with hepatitis B cirrhosis in our hospital from March 2020 to March 2022 as survey subjects,and divided them into two groups with random number table methods.Observation group was treated with tenofovir dipivoxil fumarate treatment and control group with entecavir treatment,41 cases in each group.Liver function indicators of patients before and after medication,changes in inflammatory indicators and clinical effect were compared between two groups.Results HbeAg conversion rate and HbeAb conversion rate in observation group was better than control group after treatment,difference between groups was comparable(P<0.05).Treatment effect in observation group was significantly higher than control group,data comparison showed(P<0.05),indicating statistical significance.There was no significant difference in liver function and inflammatory indicators between two groups before treatment,there was no statistical significance(P>0.05).After treatment,observation group had better liver function indicators and inflammatory factor levels than control group,difference was statistically significant(P<0.05).Conclusion Tenofovir dipivoxime fumarate can achieve significant clinical effect for patients with hepatitis B cirrhosis,can improve liver function,and reduce inflammation effectively,which has clinical value for further application and promotion in clinical practice.
Tenofovir fumarate dipivoxime esterEntecavirHepatitis B cirrhosisCurative effectLiver function
万方数据
维普
